FDA advisory panel backs use of Novartis' Entresto in heart failure

 

• The FDA's Cardiovascular and Renal Drugs Advisory Committee (CRDAC) has voted 12 to 1 supporting the use of Novartis' (NYSE:NVS) Entresto (sacubitril/valsartan) in treatment of patients with heart failure with preserved ejection fraction (HFpEF).
• This was based on data supporting the benefit of Entresto in reducing worsening heart failure in patients studied in PARAGON-HF.
• If approved, Entresto could become the first therapy as well as mediation approved for heart failure.
• The FDA decision on the sNDA is expected in Q1 2021.
• https://seekingalpha.com/news/3644765-fda-advisory-committee-backs-use-of-novartis-entresto-in-heart-failue